Sun Pharma Organon Deal: Why 2027 Decides Everything
Witfire Elite · M&A Risk Brief · Deal No. 2026-07 Sun Pharma’s $11.75B Organon Deal: Platform Acquisition or Debt-Heavy Scale Bet? Shareholders cleared the…
Witfire Coverage
Category: Pharma News
Oral PCSK9 Inhibitor Approved: LIPFENDRA Price vs Repatha
Witfire Elite · Cardiometabolic Risk Brief · Pricing & Access Oral PCSK9 Inhibitor Approved: LIPFENDRA Lists at $315. Repatha Already Sells for $239. The…
The Stabilizer Ceiling: What 3 Amyloidosis Trials Reveal
Witfire Elite · Trial Design & Strategy · Framework HELIOS-B vs CARDIO-TTRansform: What the Eplontersen Miss Reveals HELIOS-B cleared its endpoint. CARDIO-TTRansform missed. CARES…
Eplontersen CARDIO-TTRansform Miss: ATTR-CM Analysis
Witfire Elite · Trial Design & Strategy · Framework HELIOS-B vs CARDIO-TTRansform: What the Eplontersen Miss Reveals HELIOS-B cleared its endpoint. CARDIO-TTRansform missed. CARES…
Achieve Cytisinicline CRL: Rejection That Did Not Break the Company
Witfire Elite · CMC & Manufacturing Risk Brief · Case No. 2026-07 Achieve’s Cytisinicline CRL: The Rejection That Was Priced Before It Arrived Same…
Unicycive OLC CRL: The CMC Failure Behind a Biotech Selloff
Witfire Elite · CMC & Manufacturing Risk Brief · Case No. 2026-06 The CMC Execution Crisis: Why Unicycive’s Second CRL Is a Warning Shot…
AlzeCure ACD856 QuantumCell Deal: $2.2B Risk Transfer in Alzheimer’s
Witfire Elite · Licensing Risk Brief · CNS AlzeCure’s $2.2 Billion NeuroRestore Deal Is a Risk Transfer, Not a Victory AlzeCure did not prove…
Lumvoa Broke Tepezza’s Monopoly. Now Viridian Must Prove It Can Sell
Witfire Elite · Launch Execution · Competitive Strategy Lumvoa Broke Tepezza’s Monopoly. Now Viridian Must Prove It Can Sell. Viridian entered a $1.9 billion…
FDA Issues CRL to Sobi for NASP in Uncontrolled Gout
Witfire Elite · CMC & Manufacturing Risk Brief · Case No. 2026-05 FDA Issues CRL to Sobi for NASP: The Agency Rejected the Control…
Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3
Witfire Elite · Competitive Strategy · Japan Pharma Tanabe’s Uplizna Defense: Obexelimab Had Already Won Phase 3 4SigHT is formally a long-term observational study.…